| Author (ref) |
No. of pts |
IMRT platform |
Median volume |
Median dose |
Median follow-up |
PFS/local control |
Overall survival |
Late toxicity |
| Uy (23) |
40 |
Peacock-NOMOS |
20.2 cc |
50.4 Gy |
30 months |
93% (5-year) |
89% (5-year) |
5% |
| Pirzkall (24) |
20 |
KonRad, Siemens
CORVUS-NOMOS |
108 cc |
57 Gy |
36 months |
100% (imaging)
95% (clinical) |
NR |
0 |
| Sajja (25) |
35 |
Peacock-NOMOS |
NR |
50.4 Gy |
19.1 months |
97% (3-year) |
NR |
0 |
| Milker-Zabel (26) |
94 |
KonRad, Siemens |
81.4 cc |
57.6 Gy |
52 months |
95% (5-year) |
97% (5-year) |
4% |
| Combs (27) |
12 |
Helical Tomotherapy |
NR |
58 Gy |
12 months |
4/12 pts (all grade II-III) progressed |
100% |
8% |
| Luis (28) |
28 |
Helical Tomotherapy |
43.3 cc |
51.7Gy |
7.5 months |
100% (imaging) |
100% |
NR |
| Present study |
19 |
Helical Tomotherapy |
87.8 cc |
54 Gy |
32 months |
89.2% (5-year) |
100% (5-year) |
5% |
Pts=patients; PFS=progression-free survival; NR=not reported |
